semaglutide chronic kidney disease and VisualAbstract: Improves Outcomes in Patients with Type 2 Diabetes Presented at #ERA24: FLOW trial: – FDA Approves Semaglutide to Reduce

Lipo B12 injections are generally recognized as safe but do have the potential to cause similar side effects to a standard B12 injection

Protein Sci

Many patients report that they no longer feel controlled by cravings and that their eating choices feel more intentional and less reactive

Anaphylaxis is mediated by IgE antibodies

Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK

Both medications: Reduce appetite Help control cravings Improve blood sugar regulation Support long-term weight management Are administered as weekly injections Recent head-to-head clinical research found that tirzepatide users achieved approximately 20.2% average weight loss compared with 13.7% for semaglutide over 72 weeks